Introduction: Diabetes, Proteinuria, and the Kidney

Diabetes mellitus is the leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) across most developed nations. The earliest and most critical clinical hallmark of diabetic kidney disease (DKD) is the development of persistent proteinuria, specifically albuminuria. Defined as a urinary albumin-to-creatinine ratio (UACR) of 30 mg/g or greater, albuminuria is not merely a marker of glomerular damage; it is an active driver of tubulointerstitial fibrosis and a powerful, independent predictor of both CKD progression and cardiovascular mortality. The presence of proteinuria in a patient with diabetes initiates a cascade of clinical decisions aimed directly at reducing this pressure on the nephron. Central to this strategy is the blockade of the renin-angiotensin-aldosterone system (RAAS) using angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs).

Effective management of proteinuria is a primary therapeutic target in DKD. The goal is not simply blood pressure control, but the direct reduction of intraglomerular pressure and the mitigation of fibrotic pathways. This review provides a comprehensive, evidence-based overview of the role of ACEi and ARBs in managing proteinuria in diabetes, covering their mechanisms of action, key clinical trial data, comparative efficacy, integration with modern therapies, and practical management in the clinic.

The Pathophysiology of Proteinuria in Diabetic Kidney Disease

From Hyperglycemia to Structural Damage

Chronic hyperglycemia triggers a host of metabolic and hemodynamic derangements. High intracellular glucose levels lead to the formation of advanced glycation end-products (AGEs), activation of protein kinase C, and increased oxidative stress. These pathways stimulate the production of pro-inflammatory cytokines and pro-fibrotic growth factors, notably transforming growth factor-beta (TGF-β).

This biochemical assault results in progressive structural damage to the nephron:
Glomerular basement membrane (GBM) thickening: The earliest structural change, leading to a distorted filtration barrier.
Mesangial expansion: Accumulation of extracellular matrix compresses the glomerular capillaries.
Podocyte injury and loss: Podocytes are terminally differentiated cells that form the slit diaphragm, the final barrier to protein loss. Hyperfiltration and toxicity cause podocyte effacement, detachment, and apoptosis. Because they cannot regenerate, podocyte loss is a point of no return, leading to focal segmental glomerulosclerosis.

These structural defects make the filtration barrier progressively "leaky" to albumin and other proteins. The filtered proteins then wreak havoc on the tubulointerstitium, promoting inflammation and fibrosis that drive the decline in glomerular filtration rate (GFR).

The Central Role of the Renin-Angiotensin-Aldosterone System

Angiotensin II (Ang II) is the primary effector of the RAAS and is a direct mediator of kidney injury. In the diabetic kidney, local Ang II production is upregulated. Its effects are devastating for the glomerulus:
Hemodynamic effects: Ang II preferentially constricts the efferent arteriole, increasing intraglomerular hydraulic pressure. This "intraglomerular hypertension" is a primary driver of hyperfiltration and physical injury to the capillaries and podocytes.
Non-hemodynamic effects: Ang II directly stimulates TGF-β production, leading to fibrosis. It also promotes inflammation, oxidative stress, and activates aldosterone release, which independently contributes to fibrosis and sodium retention.

This dual mechanism of injury makes the RAAS the ideal pharmacologic target for renoprotection.

Clinical Staging of Proteinuria and CKD in Diabetes

Proteinuria is not a binary phenomenon; it exists on a continuum. The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 Clinical Practice Guideline for Diabetes and CKD uses the GA staging system, combining GFR (G1-G5) with albuminuria (A1-A3):
A1: Normal to mildly increased (UACR < 30 mg/g)
A2: Moderately increased (UACR 30-300 mg/g) – previously termed microalbuminuria.
A3: Severely increased (UACR > 300 mg/g) – previously termed macroalbuminuria.

The presence and severity of albuminuria (A2 or A3) dramatically increases the risk of CKD progression, kidney failure, and cardiovascular events. This risk is graphically represented by the KDIGO heat map. Patients with diabetes and A2 or A3 albuminuria are in the highest risk categories and require aggressive, multi-modal therapy. The goal of ACEi/ARB therapy is to shift a patient down the A-staging categories, or at minimum, halting the progression from A2 to A3.

Angiotensin-Converting Enzyme Inhibitors (ACEi)

Mechanism of Action

ACE inhibitors block the conversion of angiotensin I to angiotensin II. This reduces circulating and tissue levels of Ang II, leading to vasodilation of the efferent arteriole and a subsequent reduction in intraglomerular pressure. A secondary effect is the reduced breakdown of bradykinin, a vasodilatory peptide. The accumulation of bradykinin contributes to the antihypertensive and anti-proteinuric effects but is also responsible for the characteristic dry cough seen in 10-20% of patients.

Landmark Clinical Evidence

The foundational trial for ACEi in DKD was the 1993 study by Lewis et al., which demonstrated that captopril significantly reduced the risk of a doubling of serum creatinine and the combined endpoint of death, dialysis, or transplantation in patients with type 1 diabetes and proteinuria.

Since then, numerous trials have established the renoprotective benefits of other ACEi in type 2 diabetes, including enalapril, lisinopril, and ramipril. The renoprotection provided by ACEi appears to extend beyond their blood pressure-lowering effects, a concept known as "renoprotection beyond BP control."

Key Representatives and Dosing

Commonly used ACEi for proteinuria include:
Lisinopril: Starting dose 5-10 mg daily, target dose 20-40 mg daily.
Ramipril: Starting dose 2.5 mg daily, target dose 5-10 mg daily.
Enalapril: Starting dose 5 mg daily, target dose 20-40 mg daily (often divided).

Dosing should be titrated to the maximum tolerated dose to achieve the optimal anti-proteinuric effect. BP reduction alone is an insufficient endpoint for dose titration; the goal is to maximize UACR reduction while avoiding hyperkalemia or acute kidney injury (AKI).

Angiotensin Receptor Blockers (ARBs)

Mechanism of Action

ARBs selectively block the angiotensin II type 1 (AT1) receptor, through which most of the deleterious effects of Ang II are mediated. By blocking this receptor, ARBs effectively neutralize the vasoconstrictive, pro-fibrotic, and pro-inflammatory effects of Ang II. Unlike ACEi, ARBs do not inhibit bradykinin breakdown, resulting in a lower incidence of cough. They also leave the AT2 receptor unopposed; AT2 activation is thought to confer additional vasodilatory and anti-proliferative benefits.

Landmark Clinical Evidence

The renoprotective efficacy of ARBs in type 2 diabetes is exceptionally well-documented by two pivotal trials:
The RENAAL Study: Evaluated losartan in 1,513 patients with type 2 diabetes and nephropathy. Losartan reduced the risk of a doubling of serum creatinine by 25% (p=0.006) and decreased proteinuria by approximately 35%, independent of BP control.
The IDNT Study: Compared irbesartan, amlodipine, and placebo in 1,715 patients. Irbesartan reduced the risk of the primary composite endpoint (doubling of creatinine, ESRD, or death) by 20% compared to placebo and 23% compared to amlodipine.
The DETAIL Study: Directly compared telmisartan to enalapril in patients with type 2 diabetes and early nephropathy. It demonstrated non-inferiority of the ARB to the ACEi for preserving GFR, a critical head-to-head comparison.

Key Representatives and Dosing

Losartan: Starting dose 50 mg once daily, target dose 100 mg daily.
Irbesartan: Starting dose 150 mg once daily, target dose 300 mg daily.
Valsartan: Starting dose 80 mg once daily, target dose 160-320 mg daily.
Telmisartan: Starting dose 40 mg once daily, target dose 80 mg daily.

ACEi vs. ARBs: Clinical Decision-Making

Comparative Efficacy and Tolerability

Current KDIGO 2024 guidelines recommend both ACEi and ARBs as first-line therapy for the management of proteinuria in diabetes. The evidence base for both classes is robust, and they are considered broadly equivalent in terms of renoprotective efficacy. The choice between them is often driven by patient-specific factors.

Here is a summary comparison:

  • Efficacy: Equivalent for lowering UACR and slowing CKD progression.
  • Cough: Common with ACEi; rare with ARBs. ARBs are the clear choice for patients with ACEi-induced cough.
  • Angioedema: Rare but serious risk with ACEi; extremely low risk with ARBs. ARBs are generally used if a patient has a history of angioedema (though caution is still warranted).
  • Cost/Formulary: Generic ACEi are often less expensive than ARBs, though many generic ARBs are now widely available.
  • Cardiovascular Indications: Both classes are beneficial, but ACEi have a broader evidence base for post-myocardial infarction and heart failure with reduced ejection fraction (HFrEF). ARBs are standard alternatives if ACEi are not tolerated.

The Legacy of ONTARGET: Avoiding Combination Therapy

The ONTARGET trial was a landmark investigation that compared ramipril, telmisartan, and their combination. The results were definitive and practice-changing: combination therapy (ACEi + ARB) was not superior to either agent alone for any cardiovascular or renal outcome. Critically, dual blockade significantly increased the risk of hyperkalemia, symptomatic hypotension, and acute kidney injury (AKI).

Based on this, current international guidelines explicitly recommend against the routine use of combination ACEi and ARB therapy. The goal is to use a single agent at the maximally tolerated dose. If proteinuria persists despite maximal RAAS blockade, attention should turn to adjunctive therapies rather than adding a second RAAS blocker.

The Modern Paradigm: Beyond ACEi and ARBs

SGLT2 Inhibitors as Foundational Therapy

The treatment landscape for DKD has been revolutionized by the advent of sodium-glucose cotransporter-2 (SGLT2) inhibitors. The CREDENCE trial (canagliflozin) and the DAPA-CKD trial (dapagliflozin) demonstrated profound renoprotective benefits on top of maximum tolerated ACEi or ARB therapy. These trials showed a significant reduction in the progression to ESRD, cardiovascular death, and heart failure hospitalizations. The DAPA-CKD trial showed a 39% reduction in the primary composite endpoint. Current guidelines now recommend SGLT2 inhibitors as a concurrent first-line foundational therapy alongside ACEi/ARB for patients with DKD, a UACR > 200 mg/g, and an eGFR > 20 mL/min.

GLP-1 Receptor Agonists and Finerenone

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) have demonstrated benefits on albuminuria reduction and slowing of eGFR decline, largely as a secondary effect of their potent glucose and weight lowering properties, though direct anti-inflammatory effects are recognized.

Finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), has emerged as a powerful tool for residual inflammatory risk. The FIDELIO-DKD and FIGARO-DKD trials showed that finerenone, added to an ACEi or ARB (and often an SGLT2i), significantly reduces UACR and the progression of CKD, with a favorable safety profile regarding hyperkalemia compared to older MRAs like spironolactone.

Practical Management and Monitoring Strategies

Initiation and Titration

ACEi/ARB therapy should be started at a low dose and titrated upward every 2-4 weeks, guided by:

  • Blood pressure: Goal < 130/80 mmHg.
  • UACR: A reduction of 30-50% is considered a robust response.
  • Serum potassium: Must be monitored closely. A rise to > 5.5 mEq/L requires dose reduction or temporary discontinuation, along with dietary potassium restriction and optimization of concurrent medications (e.g., stopping NSAIDs).
  • Serum creatinine: A rise of up to 30% within the first 2-4 months is a hemodynamic effect and is acceptable. A rise > 30% should prompt evaluation for renal artery stenosis or volume depletion.

Safety Monitoring and Hyperkalemia Management

Hyperkalemia is the most common reason for suboptimal dosing or discontinuation of ACEi/ARB therapy. Strategies to maintain therapy include:

  • Dietary potassium restriction.
  • Avoidance of NSAIDs and high potassium supplements.
  • Correction of metabolic acidosis.
  • Use of potassium binders (e.g., patiromer, sodium zirconium cyclosilicate) in appropriate cases to allow continued therapy.

Acute kidney injury (AKI) risk increases during intercurrent illness (e.g., diarrhea, vomiting, sepsis). The recommended "sick day rule" involves temporarily holding the ACEi or ARB during vomiting/diarrhea and rehydration to avoid prerenal AKI.

Conclusion

ACE inhibitors and ARBs are indispensable, evidence-based cornerstones for the management of proteinuria in diabetic patients. By targeting the hemodynamic and fibrotic consequences of RAAS activation, they effectively lower intraglomerular pressure, reduce albuminuria, and slow the relentless progression of diabetic kidney disease. The decision between an ACEi and an ARB is typically based on tolerability, with both classes offering comparable efficacy.

Modern nephroprotection has evolved beyond single RAAS blockade. The contemporary standard of care requires the concurrent use of an SGLT2 inhibitor to maximize renoprotection. For patients with residual proteinuria or high cardiovascular risk, the addition of finerenone or a GLP-1 receptor agonist should be strongly considered. Early identification of albuminuria, prompt initiation of a maximally tolerated dose of an ACEi or ARB, and the strategic layering of newer agents offers the best chance at preserving kidney function and reducing the immense cardiovascular burden carried by patients with diabetic kidney disease.